[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100335411":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":39,"centralContacts":53,"locations":60,"responsibleParty":78,"collaborators":58,"id":81,"slug":82,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":58,"eligibilityCriteria":87,"healthyVolunteers":83,"sex":88,"minAge":89,"maxAge":58,"enrollmentInfo":90,"targetDuration":58,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":58,"overallStatus":63,"whyStopped":58,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"CHOP","ACTIVE_COMPARATOR","CHOP only",[13],"Drug: CHOP",{"label":15,"type":10,"description":16,"interventionNames":17},"CHOP Plus Lanzoprazole","CHOP Plus Lanzoprazole 60 mg",[18],"Drug: CHOP Plus Lanzoprazole",{"label":20,"type":10,"description":21,"interventionNames":22},"CHOP Plus Famotidine","CHOP Plus Famotidine 40 mg",[23],"Drug: CHOP Plus Famotidine",[25,30,35],{"type":26,"name":9,"description":11,"armGroupLabels":27,"otherNames":28},"DRUG",[9],[29],"CHOP protocol",{"type":26,"name":15,"description":31,"armGroupLabels":32,"otherNames":33},"CHOP plus Lanzoprazole 60 mg",[15],[34],"CHOP Plus Lanzoprazole 60",{"type":26,"name":20,"description":21,"armGroupLabels":36,"otherNames":37},[20],[38],"CHOP Plus Famotidine 40",[40,44,47,50],{"name":41,"affiliation":42,"role":43},"Sahar K Hegazy, Prof","Clinical pharmacy Department- Tanta University","PRINCIPAL_INVESTIGATOR",{"name":45,"affiliation":42,"role":46},"Sahar M El-Haggar, prof","STUDY_DIRECTOR",{"name":48,"affiliation":49,"role":46},"Suzan A Alhassanin, Ph D","Clinical Oncology Department-Menoufia University",{"name":51,"affiliation":52,"role":43},"Eman I A El berri, Msc","Clinical pharmacy Department-Tanta University",[54],{"name":55,"role":56,"phone":57,"phoneExt":58,"email":59},"Sherief Abd-Elsalam, MD","CONTACT","00201147773440",null,"sheriefabdelsalam@yahoo.com",[61],{"facility":62,"status":63,"city":64,"state":58,"zip":58,"country":65,"countryCode":66,"cosmosGeoPoint":67,"geoPoint":72,"contacts":73},"Sherief Abd-Elsalam","RECRUITING","Cairo","Egypt","EG",{"type":68,"coordinates":69},"Point",[70,71],31.24967,30.06263,{"lat":71,"lon":70},[74],{"name":75,"role":56,"phone":76,"phoneExt":58,"email":77},"Sherief Abd-elsalam, lecturer","00201000040794","Sherif_tropical@yahoo.com",{"type":79,"investigatorFullName":62,"investigatorTitle":80,"investigatorAffiliation":5,"oldNameTitle":58,"oldOrganization":58},"SPONSOR_INVESTIGATOR","PhDTropical Medicine","100335411","phase-3-ppi-versus-histamine-antagnists-as-adjuvant-to-chemotherapy-100335411",false,"NCT03647072","PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy","Comparative Clinical and Biochemical Study Evaluating the Effect of Proton Pump I Nhibitors Versus Histamine 2 Receptor Antagonists as an Adjuvant With Chemotherapy in Patients With Non-hodgkin Lymphoma.","Inclusion Criteria:\n\n* DLBCL Lymphoma subtype --No comorbid disease\n\nExclusion Criteria:\n\n* Pregnancy\n* Peptic ulcer\n* Severe cardiac disease\n* Osteoporosis","ALL","18 Years",{"count":91,"type":92},60,"ESTIMATED","INTERVENTIONAL",[95],"PHASE3","The study is a Comparative Clinical and Biochemical Study Evaluating the effect of Proton Pump I nhibitors versus histamine 2 Receptor antagonists as an adjuvant with chemotherapy in patients with Non-hodgkin Lymphoma.",[98],"Lymphoma","2018-08-23",{"date":101,"type":102},"2018-08-27","ACTUAL",{"date":104,"type":102},"2018-08-01",{"date":106,"type":92},"2027-12",{"name":62,"class":6},1]